GLP-1 Drugs Cut Death Risk by 42% in Diabetic Colorectal Cancer Patients | Research

The takeaway

Diabetic patients with colorectal cancer who used GLP-1 receptor agonists had 42% lower all-cause mortality and 40% lower metastasis risk compared to matched non-users.

42% lower mortality
Diabetic colorectal cancer patients on GLP-1 drugs had significantly better survival than propensity-matched non-users

What the researchers found

GLP-1RA users had significantly reduced all-cause mortality (HR 0.58, 95% CI 0.45-0.76, p<0.001) and metastasis-free survival (HR 0.60, 95% CI 0.40-0.87, p=0.01) compared to matched non-users.

Why it matters

Cancer patients with diabetes often face treatment decisions about continuing metabolic medications. This evidence supports that GLP-1 drugs may actually improve cancer outcomes.

How the study worked

Retrospective propensity-score-matched cohort study using TriNetX global health records (2010-2025) with 751 patients per cohort, analyzing overall and metastasis-free survival.

What this study cannot tell us

Retrospective observational design. Cannot prove causation. Median follow-up ~2 years. GLP-1 users may have better overall health engagement.

How to read the evidence

Large propensity-matched cohort study with strong associations. Observational design limits causal conclusions but supports continued GLP-1 use in this population.

When this study was published

Published in 2025 using data through 2025.

The bigger picture

This adds to growing evidence that GLP-1 drugs may have anti-cancer properties beyond metabolic benefits, potentially through anti-inflammatory mechanisms or direct GLP-1R effects on tumor cells.

Questions still open

What mechanisms explain GLP-1 drugs' apparent anti-cancer effects in colorectal cancer?
Should GLP-1 drugs be specifically recommended for diabetic cancer patients?
Do these survival benefits extend to other cancer types?

Common questions

Should I keep taking my GLP-1 drug if I get diagnosed with colorectal cancer?

This study suggests yes — GLP-1 drug users with diabetes and colorectal cancer had significantly better survival. Discuss with your oncologist and endocrinologist, but the data support continuing therapy.

Do GLP-1 drugs fight cancer directly?

That is still being studied. The survival benefit could come from anti-inflammatory effects, metabolic improvements, or possibly direct anti-tumor mechanisms. More research is needed to understand why GLP-1 users have better cancer outcomes.

Read the original research

Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study.

Diabetes & metabolism, 52(2), 101734

View on PubMed ↗Publisher’s paper ↗

Citation

Dosda, Arnaud; Fauchier, Grégoire; Sabbah, Nadia; Fauchier, Laurent; Lecomte, Thierry; Ducluzeau, Pierre Henri. (2026). Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study.. Diabetes & metabolism, 52(2), 101734. https://doi.org/10.1016/j.diabet.2026.101734